Heart rhythm disorders are the leading cause of morbidity and mortality in the developed world. Despite a profound difference in physiological mechanisms, anatomic and genetic determinants, and etiology of various arrhythmias, there are only two predominant treatments: electric and ablative therapies. Pharmacological therapy has been mostly ineffective or hampered by side effects. Ablative therapy for atrial tachyarrhythmias is growing in acceptance. However, the ablation procedure is complex, time-consuming, and has a number of side effects. Several modalities of electrotherapy have been effective in preventing sudden cardiac death due to ventricular tachycardia and fibrillation (VT/VF), and in arresting atrial tachycardia and fibrillation (AT/AF). However, the current bioelectric therapy paradigm has a number of limitations. Antitachycardia pacing (ATP) is the most desirable approach due to its low energy requirement, but the efficacy of ATP is limited. High- voltage biphasic shock defibrillation has evolved over the last 70 years as the dominant and highly effective electrotherapy against both AF and VF. However, the energy requirements for AF are suboptimal: high-energy shocks are painful and could cause myocardial damage. In our project we aim to address the limitations of current electrotherapy and present a novel hypothesis: multi-stage phased bioelectric therapy will allow significant reduction in DFT for atrial fibrillaton. Based on previous NIH-funded research from our laboratory we have developed an approach that terminates atrial tachyarrhythmia based on several types of multiple pulse electrotherapies with low, phased (i.e. progressively reducing) energy levels and frequencies: (1) far-field low energy multiple shocks, (2) far-field ultra-low energy entrainment stimulation, and (3) near-field entrainment pacing. We will explore two technological platforms to implement and further investigate our novel method: (1) state-of-the-art lead-based implantable device and (2) flexible electronics developed by the Rogers laboratory at the University of Illinois, Urbana-Champagne. Successful completion of this project will advance implantable bioelectric therapy of cardiac arrhythmias by (1) reducing high-voltage shock induced myocardial damage and post-shock conduction abnormalities secondary to this damage, (2) reducing pain associated with termination of tachyarrhythmias, and (3) reducing energy consumption in the implantable devices. Reduction of the DFT below 0.2J is likely to make implantable atrial defibrillation possible for millions of AF patients. Novel stretchable electronic technology developed by John A. Rogers is likely to transform electrotherapy of cardiac arrhythmias based on high anatomic resolution local sensing and multi-stage therapy of aberrant rhythms.
Atrial fibrillation (AF) is a heart rhythm disorder that affects 3-5 million Americans. There are only two predominant treatments of AF: electric and ablative therapies. High-voltage electric shock defibrillation is the dominant and highly effective electrotherapy against ventricular arrhythmias, but it is not as widely applied against AF, because the high energy shocks are painful and cannot be tolerated by patients. In our project we aim to address the limitations of current electrotherapy and present a novel hypothesis: multi-stage phased bioelectric therapy will allow significant reduction in energy required for AF defibrillation.
|Boukens, Bas J; Efimov, Igor R (2014) A century of optocardiography. IEEE Rev Biomed Eng 7:115-25|
|Janardhan, Ajit H; Gutbrod, Sarah R; Li, Wenwen et al. (2014) Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol 63:40-8|
|Sulkin, Matthew S; Boukens, Bas J; Tetlow, Megan et al. (2014) Mitochondrial depolarization and electrophysiological changes during ischemia in the rabbit and human heart. Am J Physiol Heart Circ Physiol 307:H1178-86|
|Gutbrod, Sarah R; Sulkin, Matthew S; Rogers, John A et al. (2014) Patient-specific flexible and stretchable devices for cardiac diagnostics and therapy. Prog Biophys Mol Biol 115:244-51|
|Xu, Lizhi; Gutbrod, Sarah R; Bonifas, Andrew P et al. (2014) 3D multifunctional integumentary membranes for spatiotemporal cardiac measurements and stimulation across the entire epicardium. Nat Commun 5:3329|
|Chung, Hyun-Joong; Sulkin, Matthew S; Kim, Jong-Seon et al. (2014) Stretchable, multiplexed pH sensors with demonstrations on rabbit and human hearts undergoing ischemia. Adv Healthc Mater 3:59-68|